Palvella Therapeutics, Inc. (PVLA)
138.96
+7.62
(+5.80%)
USD |
NASDAQ |
Oct 09, 16:00
138.96
0.00 (0.00%)
After-Hours: 20:00
Palvella Therapeutics EPS Diluted (Quarterly) : -1.523 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.523 |
| March 31, 2026 | -1.205 |
| December 31, 2025 | -1.082 |
| September 30, 2025 | -1.025 |
| June 30, 2025 | -0.8569 |
| March 31, 2025 | -0.7432 |
| September 30, 2024 | -3.937 |
| June 30, 2024 | -2.466 |
| March 31, 2024 | -123.38 |
| December 31, 2023 | -3.706 |
| September 30, 2023 | -8.702 |
| June 30, 2023 | 3.622 |
| March 31, 2023 | -14.15 |
| December 31, 2022 | -8.705 |
| September 30, 2022 | -10.47 |
| June 30, 2022 | -11.16 |
| March 31, 2022 | -5.536 |
| December 31, 2021 | -10.56 |
| September 30, 2021 | -19.53 |
| June 30, 2021 | -20.03 |
| March 31, 2021 | -5.929 |
| December 31, 2020 | -20.57 |
| September 30, 2020 | -21.03 |
| June 30, 2020 | -7.562 |
| March 31, 2020 | -5.212 |
| Date | Value |
|---|---|
| December 31, 2019 | -5.218 |
| September 30, 2019 | -4.202 |
| June 30, 2019 | -19.12 |
| March 31, 2019 | -16.27 |
| December 31, 2018 | -17.26 |
| September 30, 2018 | -9.101 |
| June 30, 2018 | -0.3008 |
| March 31, 2018 | -13.93 |
| December 31, 2017 | 13.31 |
| September 30, 2017 | -12.72 |
| June 30, 2017 | -18.59 |
| March 31, 2017 | -14.85 |
| December 31, 2016 | -12.19 |
| September 30, 2016 | -11.20 |
| June 30, 2016 | -11.20 |
| March 31, 2016 | -8.00 |
| December 31, 2015 | -5.60 |
| September 30, 2015 | -8.00 |
| June 30, 2015 | -9.60 |
| March 31, 2015 | -7.32 |
| December 31, 2014 | -11.38 |
| September 30, 2014 | -1186.47 |
| June 30, 2014 | -8.448 |
| March 31, 2014 | -0.678 |
| December 31, 2013 | 2.699 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Design Therapeutics, Inc. | -0.3226 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.87M |
| Total Expenses (Quarterly) | 21.87M |
| Enterprise Value | 1.663B |
| Earnings Yield | -3.48% |
| Normalized Earnings Yield | -3.460 |